Personalized Medicine Approaches for Cancer

Palo Alto (17 mi)

Overseen byLara Davis

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: OHSU Knight Cancer Institute

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?This trial tests if analyzing a patient's cancer can help find the best drugs or drug combinations to treat their disease. It targets patients with advanced cancers that are difficult to treat with standard methods. By studying the cancer cells closely, doctors can choose the best treatment options for each patient.

Eligibility Criteria

This trial is for adults with advanced breast, ovarian, prostate, or pancreatic cancer, or sarcomas who have a life expectancy of at least 6 months. They must have measurable lesions after treatment and documented progression after prior therapy. Participants need normal organ function tests and should not be pregnant or breastfeeding. Those with brain metastases, severe infections, other active cancers that could affect the study's outcome are excluded.

Treatment Details

The SMMART-ACT trial aims to see if precision medicine can find effective drug combinations based on individual cancer samples. It includes testing various drugs like Palbociclib and Trastuzumab among others for safety and effectiveness in controlling disease while also studying why treatments work differently across individuals.

1Treatment groups

Experimental Treatment

Group I: Treatment (SMMART-ACT)Experimental Treatment28 Interventions

Administered in monotherapy or in combination with other targeted agents or immunotherapies, chemotherapies, or radiation. Combination treatment plans may include a two-week monotherapy lead-in, followed by a combination treatment regimen. Each ACT study intervention must have an established RP2D determined in a prior clinical trial. Participants undergo a Pre-Treatment Biopsy, plus an On-Treatment Biopsy after two weeks on first dose of study drug(s) and prior to starting Cycle 2, regardless of regimen. Participants continue to receive study agent(s) after the On-Treatment Biopsy, according to the biopsy results and the results of ongoing safety and clinical assessments. Treatment cycles repeat every 21 to 28 days in the absence of disease progression or unacceptable toxicity. Cycles are determined based on the study agent(s). Upon disease progression, participants are given the option to undergo an additional biopsy.